Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery

Int J Mol Sci. 2021 Aug 18;22(16):8902. doi: 10.3390/ijms22168902.

Abstract

Coronavirus disease (COVID-19) is a contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This case report presents a patient who had difficulty eradicating the corona virus due to being treated with Rituximab, which depletes B lymphocyte cells and therefore disables the production of neutralizing antibodies. The combined use of external anti-viral agents like convalescent plasma, IVIG and Remdesivir successfully helped the patient's immune system to eradicate the virus without B-cell population recovery. In vitro studies showed that convalescent plasma is the main agent that helped in eradicating the virus.

Keywords: SARS-COV-2; T lymphocytes; immunocompromised; pneumonia.

Publication types

  • Case Reports

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Alanine / analogs & derivatives
  • Animals
  • Antibodies, Neutralizing / therapeutic use
  • Antibodies, Viral / immunology*
  • Antiviral Agents / therapeutic use
  • B-Lymphocytes / immunology*
  • COVID-19 / diagnostic imaging
  • COVID-19 / immunology*
  • COVID-19 / therapy*
  • COVID-19 Drug Treatment*
  • COVID-19 Serotherapy
  • Chlorocebus aethiops
  • Humans
  • Immunization, Passive
  • Immunocompromised Host
  • Rituximab / therapeutic use
  • SARS-CoV-2 / immunology*
  • T-Lymphocytes / immunology
  • Vero Cells

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antiviral Agents
  • remdesivir
  • Adenosine Monophosphate
  • Rituximab
  • Alanine